Pharmaceutical

Verastem files patent for combination treatment of FAK inhibitor and immunotherapy for cancer

Discover how Verastem Inc.'s patent combines FAK inhibitors with immunotherapeutic agents like anti-PD-1 to enhance cancer treatment efficacy in humans. Explore the innovative method targeting immune checkpoint blockade pathways.

Mar 24, 2024 - 00:00
Discover how Verastem Inc.'s patent combines FAK inhibitors with immunotherapeutic agents like anti-PD-1 to enhance cancer treatment efficacy in humans. Explore the innovative method targeting immune checkpoint blockade pathways.
Read the original article

Tags:

Previous Article

Chinook Therapeutics files patent for improving kidney function in a subject

Next Article

Ascendis Pharma files patent for ocular drug delivery system using cross-linked Ha

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Fear-based messaging doesn’t stop drug use. But it does make things worse

Opinion: Fear-based messaging doesn’t stop drug use. Bu...

May 11, 2023

STAT+: Pharmalittle: Alzheimer’s group starts lobbying for Medicare to cover new drug; U.S. judge seems sympathetic to abortion-pill challenge

STAT+: Pharmalittle: Alzheimer’s group starts lobbying ...

Mar 19, 2023

South Korean pricing reform suggests more flexible drug reimbursement negotiations

South Korean pricing reform suggests more flexible drug...

Oct 30, 2024